RE: Support and Resistance6 Mar 2025 11:13
This statement is incorrect. In fact, the National Institute for Health and Care Excellence (NICE) has recommended the Genedrive® CYP2C19-ID test as the preferred point-of-care test for CYP2C19 genotyping in the NHS.
NICE's final guidance, published in July 2024, recommends that CYP2C19 genotyping should be used to guide clopidogrel use after Ischaemic Stroke (IS) or Transient Ischaemic Attack (TIA), and specifically recommends the Genedrive® CYP2C19-ID test as the test of choice for point-of-care strategies.
The Genedrive® CYP2C19-ID Kit has demonstrated superior performance compared to traditional laboratory methods in several key areas:
1. Accuracy: The test achieved 100% sensitivity and specificity in a clinical study, outperforming laboratory platforms that produced incorrect results in 4% of samples.
2. Speed: It significantly reduced the time to results, which is crucial in emergency settings.
3. Reliability: The Genedrive test exhibited a failure rate of just 0.98%, which is three times lower than that of laboratory platforms.
4. Variant detection: It identified genetic variants in seven patients that would have been missed by both laboratory genotyping methods and competing point-of-care platforms.
Furthermore, NICE's recommendation was based on several differentiating features of the Genedrive® technology, including its greater coverage of genetic variants, no requirement for cold-chain storage logistics, and its ability to integrate with patient electronic healthcare systems.
In conclusion, far from being a "nail in the coffin," NICE's recommendation of the Genedrive® CYP2C19-ID test as the point-of-care platform of choice for CYP2C19 genotyping strategies in the NHS represents a significant endorsement and opportunity for Genedrive plc.